Recent Updates
Recently added Catalysts
DFTX Positive Sentiment

Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026

Thursday, October 29, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Definium Therapeutics will report its third quarter 2026 financial results on November 9, 2026. The webcast is scheduled for 4:30 p.m. EST, where the company will discuss its financial performance and recent business developments. This event highlights the company's ongoing efforts in the biopharmaceutical sector.

Market Sentiment Analysis

POSITIVE FACTORS

  • Definium Therapeutics is preparing to share financial results.
  • The company is focused on developing therapeutics for psychiatric disorders.
  • A webcast will provide insights into recent business highlights.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+130%
120-day peak, hindsight
Typical move
3.9%
average across 2 past catalysts
Cash runway
~59 mo
Minimal dilution risk
Lead asset
DT120
Phase 3 · Major Depressive Disorder

Full Press Release Details

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a webcast at 4:30 p.m. EST on Monday, November 9, 2026 to report financial results for the third quarter ended September 30, 2026, and discuss recent business highlights.Listeners can register for the webcast via this link

Frequently Asked Questions

When will Definium Therapeutics report its Q3 2026 results?

Definium Therapeutics will report its Q3 2026 results on November 9, 2026.

What time is the webcast for the financial results?

The webcast is scheduled for 4:30 p.m. EST.

How can I register for the webcast?

Listeners can register for the webcast via the provided link.

What will be discussed during the webcast?

The webcast will cover financial results and recent business highlights.

ShareAdd on Google
Tags: DFTX Definium Therapeutics financial results webcast biopharmaceuticals
Last updated: Oct 29, 2026

Biotech snapshot

Cash runway
$1084M liquidity · $18M/mo burn
~59 mo
Minimal dilution risk
Lead asset
DT120Phase 3
Major Depressive Disorder →

Catalyst track record

+130%
best trade around DFTX's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DFTX.

See every catalyst's timing & PoA →